Le Lézard
Classified in: Health, Business
Subjects: CXP, MAT

Trulieve Announces Opening of Medical Cannabis Dispensary in Pooler, GA


Access to medical cannabis now available at four dispensaries in the state

TALLAHASSEE, Fla., July 12, 2023 /CNW/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, today announced the grand opening of Trulieve's fourth medical cannabis dispensary in the state.

"Increasing access for Georgia's growing patient population is a responsibility we take seriously," said Kim Rivers, CEO of Trulieve. "We listen carefully to what our patients want, which in Georgia is more locations, so we are proud to open the Pooler dispensary today offering great customer service, top-quality products, patient certification and educational events."

Trulieve will host a grand opening celebration on Friday, July 14, 2023, at 10 AM with a ribbon cutting and merchandise giveaways. The new dispensary, which offers a wide range of Momenta products including nasal spray, tinctures, capsules, tincture drops and topicals, will be open 10 AM - 6 PM Tuesday through Saturday and is located at 2003 Pooler Parkway, Pooler, GA.

Trulieve offers several free resources on its website to help educate potential patients including its Find a Doctor tool, a free database visitors can use to find authorized physicians offering medical marijuana card evaluations in their area, information on recent medical cannabis studies and reviews and more information on how to become a registered patient in Georgia.

About Trulieve 

Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.

Facebook: @Trulieve
Instagram: @Trulieve_ 
Twitter: @Trulieve 

Investor Contact
Christine Hersey, Vice President of Investor Relations
+1 (424) 202-0210
[email protected]

Media Contact
Nicole Yelland, Executive Director of Corporate Communications
+1 (248) 219-9234
[email protected] 

SOURCE Trulieve Cannabis Corp.


These press releases may also interest you

at 03:14
Caliway Biopharmaceuticals (Caliway) is pleased to announce its participation to share the latest clinical advancements at the upcoming 2024 BIO International Convention on Wednesday, June 5th, at 11:45 a.m. PDT. The presentation will take place in...

10 mai 2024
On May 10, 2024, the impactful international academic journal, Science Immunology, a sub-journal of Science, published a research paper titled "Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system...

10 mai 2024
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...

10 mai 2024
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

10 mai 2024
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

10 mai 2024
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...



News published on and distributed by: